Trials / Completed
CompletedNCT02676778
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Detailed description
This is a multicenter, single-arm, open label, Phase 2 to evaluate efficacy, safety, pharmacokinetics and immunogenicity of E7777 in participants with relapsed or refractory PTCL and CTCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7777 |
Timeline
- Start date
- 2016-03-28
- Primary completion
- 2019-04-26
- Completion
- 2019-04-26
- First posted
- 2016-02-08
- Last updated
- 2021-07-15
- Results posted
- 2021-07-15
Locations
20 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02676778. Inclusion in this directory is not an endorsement.